Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25654696 | 0.93 | OPRD1 (0.45) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL25499007 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL26502247 | 0.88 | OPRD1 (0.48) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL26502625 | 0.87 | PRSS1 (0.43) | OPRD1OPRM1OPRK1QRFPRKLKB1 | |
| SCHEMBL30831318 | 0.85 | CHRNB2 (0.46) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL24406249 | 0.83 | ACE (0.43) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL25495062 | 0.82 | QRFPR (0.42) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL31365053 | 0.82 | QRFPR (0.42) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL27370284 | 0.82 | OPRD1 (0.48) | OPRD1OPRM1OPRK1QRFPRCTSB | |
| SCHEMBL25494726 | 0.82 | CTSL (0.51) | OPRD1OPRM1OPRK1CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SYSTIMMUNE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SYSTIMMUNE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023098889-A1 | ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023083381-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226207-A1 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | SLC7A1, CD44, DCLRE1A | OPRD1 3924/4885OPRM1 3807/4885OPRK1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.